Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.
Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease–human metapneumovirus (hMPV virus) and parainfluenza virus.
Join Moderna as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Track the development of Moderna’s mRNA medicines. From preclinical development to commercial phase.
Resources for journalists and media members. The latest press releases by Moderna.
Yahoo Finance: Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story
Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports ...
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying ...
Benzinga.com: Moderna Stock Explodes To New 52-Week High: What's Driving The Action?
In high-risk melanoma patients who had undergone complete tumor removal, adding Moderna's mRNA-4157 to Keytruda reduced the risk of recurrence or death by 49% versus Keytruda alone. The combination ...
Moderna (MRNA) issued the following statement on the safety of Spikevax: “The safety of Spikevax is rigorously monitored by Moderna, the U.S. FDA, and regulators in more than 90 countries. Multiple, ...
PharmiWeb: Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or ...